Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Soligenix has signed a definitive licensing agreement with the University of Colorado (CU) for a new technology which is used to develop subunit vaccines with long-term stability, including stability at elevated temperatures.
Subscribe to our email newsletter
Soligenix is developing stabilization technology under an option-to-license agreement from CU, which was executed to provide support $9.4m National Institute of Allergy and Infectious Diseases (NIAID) grant for the development of the technology.
Soligenix and CU said the license agreement has an expanded scope for thermostable vaccines for biodefense as well as all potential vaccine indications.
The novel technology involves the use of several process and formulation steps that fix sensitive vaccine ingredients in native configuration.
Soligenix chief scientific officer Robert Brey said the achievement of extended stability as well as stability under elevated temperature would represent a significant step forward in vaccine technology.
"Further, this novel thermostability technology has the potential to allow us to expand our vaccine business into the development of countermeasures against other more common infectious diseases," Brey said.